Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity
Tóm tắt
Although antiangiogenic treatment for malignant glioma using bevacizumab in combination with irinotecan chemotherapy has a promising effect on survival, the high incidence of increasing infiltrative tumors can be a problem in resistance to antiangiogenic therapy. In this study, we detected failure of bevacizumab treatment for malignant glioma through upregulation of metalloproteinase activity in the urine, as well as infiltrative tumors on MRI. In addition, MMP9 has been proved as a molecule that facilitates its infiltrative behavior in vivo in the brain animal model.
Tài liệu tham khảo
Chamberlain MC (2008) Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 26:1012–1013
Chowdhary S, Wong ET (2008) Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme: improvement over available therapy? Nat Clin Pract Neurol 4:242–243
Vredenburgh JJ, Desjardins A, Herndon JE II, et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729
Bergers G, Hanahan D (2008) Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8:592–603
Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88:169–177
Moses MA, Wiederschain D, Loughlin KR, et al (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395–1399
Takano S, Kamiyama H, Tsuboi K, et al (2004) Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 21:69–73
Ananthnarayan S, Bahng J, Roring J, et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347
Narayana A, Kelly P, Golfinos J, et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180
Norden AD, Young GS, Setayesh K, et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787
Zuniga RM, Torcuator R, Jain R, et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336
Nakada M, Nakamura H, Ikeda E, et al (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154:417–428
Smith ER, Zurakowski D, Saad A, et al (2008) Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14:2378–2386
Lucio-Eterovic A, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589–4599
Jain RK, Duda DG, Willett CG, et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327–338
Batchelor TT, Sorensen AG, di Tomaso E, et al (2007) AZD2171, a pan-VEGF receptor thyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95
Saidi A, Hagedorn M, Allain N, et al (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125:1054–1064